AVTX (Avalo Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of May 21, 2026, AVTX trades at $16.84 with a market cap of $849.46M and a P/E ratio of -2.79. AVTX moved +0.15% today. Year to date, AVTX is +1.62%; over the trailing twelve months it is +297.32%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is strong buy with an average price target of $46.78. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns AVTX stock?
Hedge funds tracked by Rallies that own AVTX include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Avalo Therapeutics, Inc. Common Stock.
AVTX Key Metrics
Key financial metrics for AVTX
Metric
Value
Price
$16.84
Market Cap
$849.46M
P/E Ratio
-2.79
EPS
$-5.84
Dividend Yield
0.00%
52-Week High
$24.27
52-Week Low
$3.39
Volume
321
Avg Volume
0
Revenue (TTM)
$59.00K
Net Income
$-78.26M
Gross Margin
0.00%
Top Hedge Funds Holding AVTX
Farallon Capital holds 916.00K shares of AVTX, changed +0.00% as of Mar 31, 2026.
Orbimed Advisors holds 475.17K shares of AVTX, changed -59.98% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own AVTX include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Avalo Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for AVTX?
Yes. Rallies tracks hedge fund and 13F ownership data for AVTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AVTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AVTX. It does not provide personalized investment advice.